2016-12-15
Ingelheim, Germany, 13 December 2016 – Having reached the milestone of 1 billion doses sold since launch, yet another vaccine of Boehringer Ingelheim Animal Health crosses a significant threshold making it one of the leading vaccines for the control of Mycoplasma hyopneumoniae globally(1).
Mycoplasma hyopneumoniae is recognized as a leading cause of respiratory disease in swine. M. hyo infection results in lung lesions, increased susceptibility to other respiratory pathogens and ultimately has a significant impact on pig health.
This milestone comes only months after two other historical events for Boehringer Ingelheim’s swine vaccine portfolio: In September 1 billion doses of Ingelvac PRRS® MLV had been sold and in October 2 billion pigs had been protected from Porcine Circovirus Disease with Ingelvac CircoFLEX®. Altogether Boehringer Ingelheim Animal Health has now been able to protect 4 billion pigs against PRRS, PCV 2 and M. hyo.
George Heidgerken, Head of Boehringer Ingelheim Animal Health, states: “We are proud of our swine vaccine portfolio and the achievement of multiple milestones over the last months, including reaching 1 billion doses of Ingelvac MycoFLEX® now. M. hyo infection has a negative effect on animal wellbeing and can cause major economic losses in pig production. Controlling infections, which includes management interventions and vaccination with Ingelvac MycoFLEX® provides optimum results.”
The swine vaccine Ingelvac MycoFLEX® is registered in 58 countries and based on the ImpranFLEX® Adjuvant Platform, which allows for fresh, on-farm mixing with Ingelvac CircoFLEX® to form FLEXcombo®. FLEXcombo® provides proven protection against Porcine Circo virus and M. hyo without compromising efficacy and safety with just one single shot around weaning.
Ingelvac MycoFLEX® is also the trusted mixing partner for 3FLEX®, the only approved combination vaccine to protect against 3 of the most devastating swine diseases; PCV2, M. hyo and PRRS, with a single injection(2).
